EP0592127A1 - Immunoassay for isothiazolones - Google Patents
Immunoassay for isothiazolones Download PDFInfo
- Publication number
- EP0592127A1 EP0592127A1 EP93307558A EP93307558A EP0592127A1 EP 0592127 A1 EP0592127 A1 EP 0592127A1 EP 93307558 A EP93307558 A EP 93307558A EP 93307558 A EP93307558 A EP 93307558A EP 0592127 A1 EP0592127 A1 EP 0592127A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- isothiazolones
- antibodies
- antibody
- isothiazolone
- hybridoma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- JLHMJWHSBYZWJJ-UHFFFAOYSA-N 1,2-thiazole 1-oxide Chemical class O=S1C=CC=N1 JLHMJWHSBYZWJJ-UHFFFAOYSA-N 0.000 title claims abstract description 97
- 238000003018 immunoassay Methods 0.000 title claims abstract description 15
- 210000004408 hybridoma Anatomy 0.000 claims abstract description 69
- 238000000034 method Methods 0.000 claims abstract description 53
- 239000000203 mixture Substances 0.000 claims abstract description 27
- 230000002163 immunogen Effects 0.000 claims abstract description 21
- 229920002521 macromolecule Polymers 0.000 claims abstract description 18
- DHNRXBZYEKSXIM-UHFFFAOYSA-N chloromethylisothiazolinone Chemical compound CN1SC(Cl)=CC1=O DHNRXBZYEKSXIM-UHFFFAOYSA-N 0.000 claims abstract description 16
- 210000004027 cell Anatomy 0.000 claims description 67
- 241001465754 Metazoa Species 0.000 claims description 28
- 239000000126 substance Substances 0.000 claims description 23
- 210000000628 antibody-producing cell Anatomy 0.000 claims description 16
- 210000004881 tumor cell Anatomy 0.000 claims description 15
- 210000002966 serum Anatomy 0.000 claims description 14
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 claims description 10
- 210000004369 blood Anatomy 0.000 claims description 10
- 239000008280 blood Substances 0.000 claims description 10
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 claims description 10
- 230000003053 immunization Effects 0.000 claims description 9
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 7
- 208000007452 Plasmacytoma Diseases 0.000 claims description 7
- 239000003153 chemical reaction reagent Substances 0.000 claims description 7
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 7
- 210000000952 spleen Anatomy 0.000 claims description 7
- 239000000427 antigen Substances 0.000 claims description 6
- 102000036639 antigens Human genes 0.000 claims description 6
- 108091007433 antigens Proteins 0.000 claims description 6
- 239000012530 fluid Substances 0.000 claims description 6
- TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 claims description 5
- 206010003445 Ascites Diseases 0.000 claims description 5
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 claims description 5
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 claims description 5
- 229960003896 aminopterin Drugs 0.000 claims description 5
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 claims description 5
- 229940104230 thymidine Drugs 0.000 claims description 5
- 108010091358 Hypoxanthine Phosphoribosyltransferase Proteins 0.000 claims description 3
- 230000002950 deficient Effects 0.000 claims description 3
- 241000283984 Rodentia Species 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims description 2
- 230000012010 growth Effects 0.000 claims description 2
- BEGLCMHJXHIJLR-UHFFFAOYSA-N methylisothiazolinone Chemical group CN1SC=CC1=O BEGLCMHJXHIJLR-UHFFFAOYSA-N 0.000 claims description 2
- 102000018251 Hypoxanthine Phosphoribosyltransferase Human genes 0.000 claims 1
- 239000012141 concentrate Substances 0.000 claims 1
- 239000000243 solution Substances 0.000 description 29
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 19
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 18
- 239000003112 inhibitor Substances 0.000 description 18
- 239000002609 medium Substances 0.000 description 18
- 238000003556 assay Methods 0.000 description 17
- 102000004190 Enzymes Human genes 0.000 description 14
- 108090000790 Enzymes Proteins 0.000 description 14
- 239000000872 buffer Substances 0.000 description 13
- 150000001875 compounds Chemical class 0.000 description 13
- 239000000758 substrate Substances 0.000 description 13
- 239000000463 material Substances 0.000 description 12
- -1 pentachlorophenol Chemical class 0.000 description 12
- 239000006228 supernatant Substances 0.000 description 12
- 239000011159 matrix material Substances 0.000 description 11
- 238000002835 absorbance Methods 0.000 description 10
- 239000012528 membrane Substances 0.000 description 10
- 239000007787 solid Substances 0.000 description 10
- 235000012431 wafers Nutrition 0.000 description 10
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 238000004113 cell culture Methods 0.000 description 7
- 238000010367 cloning Methods 0.000 description 7
- 239000002023 wood Substances 0.000 description 7
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- 229940093499 ethyl acetate Drugs 0.000 description 6
- 235000019439 ethyl acetate Nutrition 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 5
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 5
- 241000700159 Rattus Species 0.000 description 5
- 239000011248 coating agent Substances 0.000 description 5
- 238000000576 coating method Methods 0.000 description 5
- 238000001816 cooling Methods 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 229920001223 polyethylene glycol Polymers 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 238000012216 screening Methods 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 210000003719 b-lymphocyte Anatomy 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 230000006957 competitive inhibition Effects 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 230000004927 fusion Effects 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 239000004033 plastic Substances 0.000 description 4
- 229920003023 plastic Polymers 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 4
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 3
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 3
- PORQOHRXAJJKGK-UHFFFAOYSA-N 4,5-dichloro-2-n-octyl-3(2H)-isothiazolone Chemical compound CCCCCCCCN1SC(Cl)=C(Cl)C1=O PORQOHRXAJJKGK-UHFFFAOYSA-N 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 239000004793 Polystyrene Substances 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- DKQYKQNEEYKIDM-UHFFFAOYSA-N methyl 4-(3-oxo-1,2-thiazol-2-yl)butanoate Chemical compound COC(=O)CCCN1SC=CC1=O DKQYKQNEEYKIDM-UHFFFAOYSA-N 0.000 description 3
- MHGPTTDXFIMHMY-UHFFFAOYSA-N methyl 4-(5-chloro-3-oxo-1,2-thiazol-2-yl)butanoate Chemical compound COC(=O)CCCN1SC(Cl)=CC1=O MHGPTTDXFIMHMY-UHFFFAOYSA-N 0.000 description 3
- 229920002223 polystyrene Polymers 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000009257 reactivity Effects 0.000 description 3
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- YOETUEMZNOLGDB-UHFFFAOYSA-N 2-methylpropyl carbonochloridate Chemical compound CC(C)COC(Cl)=O YOETUEMZNOLGDB-UHFFFAOYSA-N 0.000 description 2
- YCLSOMLVSHPPFV-UHFFFAOYSA-N 3-(2-carboxyethyldisulfanyl)propanoic acid Chemical compound OC(=O)CCSSCCC(O)=O YCLSOMLVSHPPFV-UHFFFAOYSA-N 0.000 description 2
- VURCJRMYKFUQSW-UHFFFAOYSA-N 3-[(3-chloro-3-oxopropyl)disulfanyl]propanoyl chloride Chemical compound ClC(=O)CCSSCCC(Cl)=O VURCJRMYKFUQSW-UHFFFAOYSA-N 0.000 description 2
- JNWGRCYCKMOLQW-UHFFFAOYSA-N 4-(5-chloro-3-oxo-1,2-thiazol-2-yl)butanoic acid Chemical compound OC(=O)CCCN1SC(Cl)=CC1=O JNWGRCYCKMOLQW-UHFFFAOYSA-N 0.000 description 2
- 108090001008 Avidin Proteins 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 102100029098 Hypoxanthine-guanine phosphoribosyltransferase Human genes 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 229960000583 acetic acid Drugs 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 238000001261 affinity purification Methods 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 150000008064 anhydrides Chemical class 0.000 description 2
- 125000003710 aryl alkyl group Chemical group 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 108010030694 avidin-horseradish peroxidase complex Proteins 0.000 description 2
- 239000003139 biocide Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 239000012267 brine Substances 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 235000013861 fat-free Nutrition 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 125000001475 halogen functional group Chemical group 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 150000002431 hydrogen Chemical group 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 230000008105 immune reaction Effects 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 239000010985 leather Substances 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000012038 nucleophile Substances 0.000 description 2
- 239000012044 organic layer Substances 0.000 description 2
- IZUPBVBPLAPZRR-UHFFFAOYSA-N pentachlorophenol Chemical compound OC1=C(Cl)C(Cl)=C(Cl)C(Cl)=C1Cl IZUPBVBPLAPZRR-UHFFFAOYSA-N 0.000 description 2
- 150000002989 phenols Chemical class 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- QLNJFJADRCOGBJ-UHFFFAOYSA-N propionamide Chemical compound CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 description 2
- 229940080818 propionamide Drugs 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 150000003573 thiols Chemical class 0.000 description 2
- 125000006702 (C1-C18) alkyl group Chemical class 0.000 description 1
- 125000006552 (C3-C8) cycloalkyl group Chemical class 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004189 3,4-dichlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(Cl)C([H])=C1* 0.000 description 1
- 125000006283 4-chlorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1Cl)C([H])([H])* 0.000 description 1
- 125000004217 4-methoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1OC([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102000008857 Ferritin Human genes 0.000 description 1
- 108050000784 Ferritin Proteins 0.000 description 1
- 238000008416 Ferritin Methods 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- 241000893859 Matelea Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 235000005018 Pinus echinata Nutrition 0.000 description 1
- 241001236219 Pinus echinata Species 0.000 description 1
- 235000011334 Pinus elliottii Nutrition 0.000 description 1
- 235000017339 Pinus palustris Nutrition 0.000 description 1
- 235000008566 Pinus taeda Nutrition 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- 108010034949 Thyroglobulin Proteins 0.000 description 1
- 102000009843 Thyroglobulin Human genes 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000002981 blocking agent Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 1
- 239000003593 chromogenic compound Substances 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 239000012039 electrophile Substances 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical group 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000000984 immunochemical effect Effects 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 230000009851 immunogenic response Effects 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 238000005555 metalworking Methods 0.000 description 1
- KVQGGLZHHFGHPU-UHFFFAOYSA-N methyl 4-aminobutanoate Chemical compound COC(=O)CCCN KVQGGLZHHFGHPU-UHFFFAOYSA-N 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 238000007431 microscopic evaluation Methods 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000010807 negative regulation of binding Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- JPMIIZHYYWMHDT-UHFFFAOYSA-N octhilinone Chemical compound CCCCCCCCN1SC=CC1=O JPMIIZHYYWMHDT-UHFFFAOYSA-N 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 238000000611 regression analysis Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000007142 ring opening reaction Methods 0.000 description 1
- 238000010079 rubber tapping Methods 0.000 description 1
- 239000012898 sample dilution Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229960002175 thyroglobulin Drugs 0.000 description 1
- IMFACGCPASFAPR-UHFFFAOYSA-N tributylamine Chemical compound CCCCN(CCCC)CCCC IMFACGCPASFAPR-UHFFFAOYSA-N 0.000 description 1
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54353—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals with ligand attached to the carrier via a chemical coupling agent
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/815—Test for named compound or class of compounds
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
- Y10T436/141111—Diverse hetero atoms in same or different rings [e.g., alkaloids, opiates, etc.]
Definitions
- This invention relates to methods of detection of low concentrations of isothiazolone compounds using immunoassays.
- Isothiazolone compounds are widely used as biocides in many applications where water or moisture is present. In many of those applications, there is a need to determine the proper dosage and stability of the isothiazolone in the system.
- the present state of the art is to use HPLC analytical methods which are time consuming, inconvenient, and expensive.
- Westinghouse Electric Corporation EP 260829A discloses monoclonal antibodies which react with chlorinated phenols, particularly pentachlorophenol, and hybridomas which produce such antibodies; and an immunoassay for such chlorinated phenols. Although detection methods for many compounds would benefit greatly by development of an immunoassay, appropriate cell lines are very difficult to create.
- U.S. 4,865,972 discloses an antibody based assay for enzyme-inducing chemicals (such as dibenzodioxins). Isothiazolones are not enzyme-inducing compounds.
- novel antibodies which satisfy a number of critical needs not fulfilled by existing analytical technology. Such antibodies allow the detection of isothiazolone by a variety of rapid, simple, and cost effective immunoassay techniques.
- the novel antibodies are particularly useful for analyzing the isothiazolone compound in water, since the isothiazolone does not have to be extracted first.
- the present invention comprises in one aspect a method of preparing an immunogenic conjugate of an isothiazolone and a macromolecule carrier, comprising covalently attaching a macromolecule carrier to an isothiazolone containing a reactive group, preferably via a chemical linker; immunizing an animal with said immunogenic conjugate; obtaining antibody-producing cells from said animal; fusing said cells with tumour cells to produce hybridomas; selecting from among said hybridomas at least one hybridoma that produces antibodies able to bind specifically with said isothiazolones; and recovering said produced antibodies from said selected hybridoma.
- the invention is also directed to immunogenic conjugates of isothiazolones and a macromolecule carrier and to methods of making such conjugates.
- the invention comprises a method of producing polyclonal antibodies reactive with isothiazolones, comprising obtaining an immunogenic conjugate as described above; immunizing an animal with said conjugate; removing blood from said animal; separating the serum from said blood; and recovering polyclonal antibodies from said serum.
- the invention is directed to the antibodies, processes of preparing the antibodies, analytic, diagnostic, investigational, separatory, and the other methods of using the antibodies, and compositions containing the antibodies for such uses.
- the invention is directed to hybridomas that produce the monoclonal antibodies and to methods of making the hybridomas.
- FIG. 1 is a graph showing the percent inhibition of binding of four different species of isothiazolones of a immunoassay according to the invention.
- the isothiazolones as a class are very reactive electrophiles having a first order rate constant for reaction with thiols of 1.053 x 103 mol/sec (P.J. Collier et al., J. Appl. Bacteriol., 69:578-584, 1991). Also, 5-chloro-2-methyl-3-isothiazolone has the capability of reacting further after the ring-opening reaction with thiols. It is well know that blood sera and red blood cells contain high levels of glutathione, a reduced thiol compound.
- Monoclonal antibodies are derived from a single B-lymphocyte clone ("hybridoma") which makes them very specific and homogeneous. Such a hybridoma is, in fact, a self-reproducing cell "factory" which can produce a potentially limitless supply of an antibody with single, pre-defined specificity.
- R1 and R2 are each independently hydrogen, halogen or a (C1-C4) alkyl group or alternatively may be joined to form a saturated, unsaturated or aromatic 5- or 6-membered fused carbocyclic ring;
- Y is hydrogen, an unsubstituted or halo-substituted (C1-C18) alkyl group, an unsubstituted or halo-substituted alkenyl or alkynyl group of 2 to 8 carbons, an unsubstituted or halo-substituted (C3-C8) cycloalkyl, an (C7-C10)aralkyl or halo-, (C1-C4) alkyl-, or (C1-C4) alkoxy-substituted (C7-C10)aralkyl, or an aryl or halo-, (C1-C4) alkyl-, or (
- Y substituents include methyl, ethyl, propyl, isopropyl, butyl, hexyl, octyl, cyclohexyl, 4-methoxyphenyl, 4-chlorophenyl, 3,4-dichlorophenyl, benzyl, 4-methoxybenzyl, 4-chlorobenzyl, phenethyl, 4-phenylbutyl, chloromethyl, chloropropyl, hydrogen and the like.
- the most preferred isothiazolone is 5-chloro-2-methyl-3-isothiazolone.
- the monoclonal antibodies are made by producing an immunogenic conjugate of the isothiazolones and a macromolecule carrier, immunizing an animal with the conjugate, obtaining antibody-producing cells from the animal, fusing the cells with tumour cells to produce hybridomas, selecting from among the hybridomas at least one that produces antibodies reactive with isothiazolones, and recovering the produced antibodies from the selected hybridoma.
- An in vivo method of producing monoclonal antibodies reactive with isothiazolones involves intraperitoneally placing in a histocompatible or immunosuppressed host a hybridoma that produces such antibodies and recovering the produced antibodies from the ascites fluid of the host.
- a continuous cell line that produces monoclonal antibodies to isothiazolones is prepared by producing an immunogenic conjugate of the isothiazolones and a macromolecule carrier, immunizing an animal with the conjugate, obtaining antibody producing cells from the animal, fusing the antibody-producing cells with tumor cells to produce hybridomas, selecting from among the hybridomas a hybridoma that produces antibodies reactive with the isothiazolones, and clonally expanding the selected hybridoma into a cell line.
- the antibodies produced by the continuous cell line selected are referred to as "anti-651" antibodies.
- monoclonal antibodies reactive with the isothiazolones are added to the sample and the presence or concentrations of the isothiazolones is determined by an immunoassay wherein the monoclonal antibodies are used as a reagent.
- the monoclonal antibodies are preferably provided in an acceptable carrier.
- the anti-651 antibody can be coupled to the enzyme horseradish peroxidase ("HRP") using standard procedures.
- HRP horseradish peroxidase
- This coupled enzyme-antibody can be used as an immunological stain to determine the location of isothiazolones in solid matrices such as wood, leather and plastics.
- the matrix to be examined is sectioned into thin slices by an appropriate method, and then incubated with the coupled enzyme-antibody for a period of time, during which it reacts with the isothiazolone or isothiazolones. After incubation, the unbound enzyme-antibody is removed by washing with buffer, such as PBS-Tween. Next, the treated matrix material is incubated with enzyme substrate, of which a number of commercially available chromogenic compounds are available.
- the matrix is treated with the substrate in such a volume that the coloured product does not diffuse away from the site of reaction.
- the substrate may be incorporated into a membrane which is overlaid on the treated substrate.
- An example of such a product is the Enzygraphic Web from International Biotechnologies Inc. ("IBZ").
- IBZ International Biotechnologies Inc.
- the isothiazolone is localized by visual or microscopic examination of the matrix, or of the substrate-impregnated membrane.
- enzyme coupled antibody An alternative to the use of enzyme coupled antibody is the use of ferritin or gold-labelled antibody, or the use of radio-labelled antibodies. Radio-labelled antibodies require the exposure of the treated matrix to photographic film.
- the antibody can also be used to determine the presence and concentration of isothiazolones in a solid matrix, such as wood, plastic or leather.
- the solid matrix can be tested for the presence of isothiazolone by soaking wafers of the matrix in a solution of a protein blocking agent, such as nonfat milk or Bovine Serum Albumin ("BSA”), for 30-60 minutes.
- a protein blocking agent such as nonfat milk or Bovine Serum Albumin (“BSA”)
- BSA Bovine Serum Albumin
- the wafers are then rinsed briefly with PBS-Tween (PBS-T) buffer, and exposed to the anti-651 antibody, which is covalently linked to horseradish peroxidase, for 15 minutes.
- the wafers are then washed twice for a period of time each in PBS-T buffer.
- the bound anti-651-HRP complex can then be visualized by placing the wafers in a vial containing HRP substrate, such as ABTS (2,2'-azino-bis-3- ethylbenzthiazolin-6-sulfonic acid).
- HRP substrate such as ABTS (2,2'-azino-bis-3- ethylbenzthiazolin-6-sulfonic acid.
- the enzyme substrate can be placed on the surface of the wood either as a solution or as a substrate affixed to a solid support, such as the commercially available Enzygraphic Web (IBI).
- IBI Enzygraphic Web
- An immunological procedure can be employed for the isolation or removal of isothiazolones from a mixture on the basis of a selective immunological reaction in which a monoclonal antibody reactive with the isothiazolones is used as the antibody.
- a composition for isolating or removing an isothiazolone compound from a mixture containing said compound comprises an effective amount of monoclonal antibody reactive with the isothiazolone compound, immobilized on a matrix or in admixture with a carrier.
- Polyclonal antibodies reactive with isothiazolone compound are produced by producing an immunogenic conjugate of the isothiazolone and a macromolecule carrier, immunizing an animal with the conjugate, removing blood from the animal, separating the serum from the blood, and recovering the antibodies from the serum.
- An immunogenic conjugate comprising isothiazolone compound covalently bonded to a macromolecule carrier is produced by covalently attaching a chemical linker to the macromolecule carrier and covalently attaching a derivative of the isothiazolone, such derivative containing a reactive group, to the chemical linker, thereby forming the immunogenic conjugate.
- the monoclonal antibodies of the present invention have the characteristics of the monoclonal antibodies produced by the hybridoma cell line ATCC HB 11435 or mutants or variants thereof.
- ATCC HB 11435 is a biologically pure culture available from the permanent collection of the American Type Culture Collection (ATCC), 12301 Parklawn Drive, Rockville, Maryland USA 20852 and was deposited on May 14, 1991.
- ATCC HB 11435 was produced by fusion of a mouse B-lymphocyte and a mouse plasmacytoma cell.
- the immunoglobulins (antibodies) produced by these hybridomas are of the IgG class.
- the monoclonality of ATCC HB 11435 antibodies was ensured by re-cloning the hybridomas which produced them.
- the monoclonal antibodies produced by ATCC HB 11435 will prevent other monoclonal antibodies that would otherwise react with 5-chloro-2-methyl- 3-isothiazolone, which have been produced by other hybridomas, from so reacting.
- the hybridomas and continuous cell lines can be prepared by:
- the monoclonal antibodies can be recovered from the selected hybridoma or hybridomas before or after they are expanded by cloning into a continuous cell line.
- cells other than spleen cells can be used to produce antibodies to isothiazolones.
- the hybridomas produced by this embodiment can be used to produce the monoclonal antibodies of the invention by culturing them in a suitable medium and recovering the antibodies from the medium.
- the methods of Albro et al. and Stark involve covalently bonding the hapten to the macromolecule carrier through a chemical bridge or linker.
- the chemical linker is a bifunctional molecule that contains reactive groups on opposite ends. The reactive groups allow the chemical linker to react with reactive groups on the macromolecule and on the hapten so that one end of the chemical linker is covalently bonded to the hapten.
- the chemical linker is added first to the hapten and the resulting compound is then added to the macromolecule carrier through the reactive group at the other end of the chemical linker.
- the immunogenic conjugate Once the immunogenic conjugate has been produced, it is used to immunize an animal host known by techniques. Such techniques usually involve inoculation, but they may involve other modes of administration. A sufficient amount of the conjugate is administered to create an immunogenic response in the animal host.
- Any host that produces antibodies to the conjugate may be used.
- Conventionally used animals include rabbits and rodents, such as rats or mice. Mice and rats are preferred for the present invention.
- polyclonal antibodies may be recovered by techniques known in the art.
- the general method comprises removing blood from the animal and separating the serum from the blood.
- the serum which contains antibodies to the isothiazolones used as the hapten in the preparation of the conjugate, may be used as an antiserum to the isothiazolones.
- the antibodies can be recovered from the serum.
- Affinity purification is a preferred technique for recovering purified polyclonal antibodies to isothiazolones from the serum.
- Monoclonal antibody-producing cells are recovered from the immunized animal. Although any antibody-producing cells may be used, B-lymphocytes obtained from the animal's spleen are preferred.
- tumour cell includes any cell that is capable of fusing with an antibody-producing cell to create a hybrid "immortal" cell, i.e., one which is capable of continuous growth in vitro .
- Preferred tumour cells are antibody-producing cells which have been transformed and which have lost their ability to produce immunoglobulin. Such cells include rat myeloma cells and mouse plasmacytoma cells.
- mouse plasmacytoma cells or rat myeloma cells that are deficient in the enzyme hypoxanthinequanine phosphoribosyl transferase (HGPRT), which allows the selection of hybridomas from unfused antibodying-producing cells or plasmacytoma or myeloma cells when grown on a medium containing hypoxanthine, aminopterin and thymidine.
- HGPRT hypoxanthinequanine phosphoribosyl transferase
- tumour cells useful for fusing with antibody-producing cells are known and readily available.
- One such type of cell is the mouse plasmacytoma cell line P3-X63-Ag8.653., described in Kearney, J. Immunology, 123. 1548 (1979).
- Another cell line is the rat myeloma cell line YB2.0, described in Milstein, J . Cell Biology , 93:576-582 (1982).
- ATCC CRL 1580 and ATCC CRL 1662 are available from American Type Culture Collection, Rockville, Maryland, where they are designated ATCC CRL 1580 and ATCC CRL 1662 respectively.
- the antibody-producing cell and the tumour cell can be from different animal species. For example, see Nowinski, et al. Science , 210:537 (1980).
- the hybridomas will be naturally selected since the tumour cells are unable to survive on such a medium.
- other known selection techniques may also be used.
- the hybridomas are selected, they are evaluated to determine which are producing antibodies to the isothiazolones.
- Various immunoassays known to those skilled in the art may be used to evaluate the culture supernatants of the hybridomas. Care must be taken to identify hybridomas that are producing monoclonal antibodies only to the isothiazolones rather than to the isothiazolone-macromolecule carrier. That is, the monoclonal antibodies which are desired, useful, and provided by this invention are those that react with free, i.e., unconjugated or unbound isothiazolones.
- the preferred selection technique is an initial screen by an enzyme immunoassay (EIA) to identify hybridomas producing antibodies to the conjugate or to the isothiazolones. These hybridomas are then screened by a competitive inhibition enzyme immunoassay (CIEIA) that evaluates the ability of a free isothiazolone, such as 5-chloro-2-methyl-3-isothiazolone, to inhibit the binding of monoclonal antibodies to the isothiazolone/protein carrier.
- EIA enzyme immunoassay
- CIEIA competitive inhibition enzyme immunoassay
- the antibodies can be recovered from such hybridomas by known techniques. Generally, it is useful to clone one or more of the monoclonal antibody-producing hybridomas to expand it into a continuous cell line that can be used to produce the monoclonal antibodies in quantity.
- An in vivo process for producing monoclonal antibodies to isothiazolones includes placing a hybridoma that produces the antibodies intraperitoneally in a histocompatible or immunosuppressed host. This causes the host to produce ascites tumors which, in turn, produce a fluid that contains the monoclonal antibodies produced by the hybridoma. After a sufficient time has passed for the antibodies to have been produced in sufficient quantities, they may be recovered by known techniques. For example, the ascites fluid may be removed and the monoclonal antibodies recovered in pure form by affinity purification. This method is particularly suitable for producing the monoclonal antibodies in commercially useful quantities.
- the monoclonal and polyclonal antibodies can be used to identify isothiazolones, particularly 5-chloro-2-methyl-3-isothiazolone, in materials and to determine the concentration of the chemical in those materials. Such materials include, for example, soil, water, food, and body fluids.
- the antibodies of the present invention provide an improved assay. Detection is convenient, rapid, sensitive, and specific.
- the immunoassays in which the antibodies of the present invention may be used include, but are not limited to, radioimmunoassay, competition immunoprecipitation assay, enzyme-linked immunoabsorbent assay, and immunofluorescence assay.
- the monoclonal antibodies of the present invention are generally the preferred antibodies, although the polyclonal antibodies are preferred in certain applications.
- a composition for determining the presence or concentration of isothiazolones in material contains a concentration of antibodies to the chemical effective to detect the presence of the chemical or to quantify its amount.
- the antibodies can be mixed with or attached to any suitable carrier, such as a latex particle or plastic microtiter plate. They may also be conjugated with an enzyme or dye or radio-labelled, depending upon what immunological method is employed. Consequently, any assay system which employs monoclonal or polyclonal antibodies with isothiazolones, including 5-chloro-2-methyl-3-isothiazolone, is embraced by this invention.
- the monoclonal and polyclonal antibodies are also useful for the isolation, purification, neutralization, and/or removal of isothiazolones from complex mixtures of solutions on the basis of a selective immunological reaction.
- the use of antibodies reactive with isothiazolones represents an improvement over the known methods.
- Monoclonal antibodies are preferred over polyclonal antibodies. Because of their great specificity and their availability in virtually limitless quantities, monoclonal antibodies can be used on a large industrial or commercial scale. For example, anti-651 antibodies are useful to separate and purify 5-chloro-2-methyl-3-isothiazolone from a mixture of other isothiazolones or similar organic compounds. The mixture is brought into contact with immobilized monoclonal antibodies to 5-chloro-2-methyl-3-isothiazolone, which separates the 5-chloro-2-methyl-3-isothiazolone from the mixture by forming immobilized complexes of the 5-chloro-2-methyl-3-isothiazolone bound to the antibody. After the mixture is removed, the 5-chloro-2-methyl-3-isothiazolone is separated from the antibodies and recovered in purified form by known techniques.
- a composition useful for purifying or removing isothiazolones from complex mixtures contains an effective amount of the monoclonal antibody immobilized on an acceptable matrix or in admixture with an acceptable carrier, to permit reaction and binding with isothiazolones.
- polyclonal antibodies may be preferred.
- the monoclonal antibodies of this invention are also useful reagents for research related to the structure and function of isothiazolones, particularly 5-chloro-2-methyl-3-isothiazolone. Their specificity allows them to be used for immunochemical and structure-activity analyses of these chemicals, and makes them more useful in these applications than less specific polyclonal antibodies.
- compositions are also useful as investigational reagents.
- a light, white powder (651-BSA conjugate) was obtained (2.9 g).
- the conjugates of 651 to THY (651-THY), 573 to BSA (573-BSA), and 573 to THY (573-THY) were prepared in a similar manner.
- mice were obtained from Taconic Farms, New York, USA, and immunized with 651-BSA, 651-THY, 573-BSA or 573-THY conjugates produced in the previous Example according to the schedule set forth in Table I in which CFA is "Complete Freund's Adjuvant,” IFAM “Incomplete Freund's Adjuvant,” PBS is "Physiologically Buffered Saline,” “sc” is subcutaneous, and “ip” is intraperitoneal.
- Adjuvant Route 1 12/7/88 300 ug CFA sc 63 2/8/89 150 ug IFA sc 119 4/5/89 100 ug IFA sc 314 10/17/89 100 ug IFA sc 403 1/14/90 50 ug IFA sc 499 4/20/90 30 ug PBS ip 499 4/20/90 20 ug PBS sc 573 7/3/90 100 ug PBS ip
- the wells then received 50 ⁇ l of buffer alone (PBS-T) or inhibitors, either 651 or 573, each diluted to 2 ppm in buffer.
- the wells then received 50 ⁇ l of mouse serum, so that each serum was reacted with either buffer, 651 or 573 (inhibitors).
- the combination of equal volumes of sera and inhibitors or buffer resulted in a final concentration of inhibitors of 1 ppm.
- the wells were incubated for 30-60 minutes at room temperature.
- the antibody molecules would bind to the inhibitors, and would therefore form an antibody-inhibitor complex which would stay in solution and be removed from the plate during the washing step.
- the binding of the antibody to the inhibitor would reduce the number of antibody molecules available to bind to the coating antigen, 651-BSA. Because fewer antibody molecules are attached to the 651-BSA, there is a reduction in the number of biotinylated horse anti-mouse IgG molecules bound, resulting in fewer molecules of avidin-peroxidase complex being bound, resulting in reduced hydrolysis of the substrate, leading ultimately to lower absorbances.
- Table 1A The data are shown in Table 1A. In all cases, the inhibitor concentration was 10 ⁇ 4 M.
- mouse 1E immunized with 573-THY, produced serum with antibodies reactive toward both 651 and 573.
- the diluted cells were counted on a hemocytometer to obtain an approximation of the number of lymphocytes obtained from the spleen. During this time, the cells were pelletted by centrifugation at approximately 200 x g for 5 minutes at room temperature.
- 1.2 x 108 lymphocytes were obtained from the spleen. These were mixed with 1.2 x 107 myeloma cells (SP2/0-Ag14, ATCC Cat CRL1581). The cells were again pelletted by centrifugation (approximately 250 x g for 10 minutes at room temperature). The supernatant was removed to near dryness and the cells resuspended by gently tapping the centrifuge tube to loosen the cell pellet.
- the cells were then treated with 1 ml of 50% polyethylene glycol, mw 1500 (PEG), which had been prewarmed to 36° C.
- PEG polyethylene glycol
- the PEG was added slowly (dropwise) over a period of approximately 75 seconds, with constant rotating of the centrifuge tube to insure that the cells remained well mixed while in contact with PEG.
- the centrifuge tube containing the cells was then placed in a 37°C water bath for 1 minute.
- the tube was then removed from the water bath and 1 ml of warm ABC medium was added dropwise during the next 60-75 seconds with constant rotating of the centrifuge tube to insure that the cells and PEG were well mixed with the medium.
- the cells were again transferred to the 37° C water bath for 1 minute and then removed from the water bath.
- 2 ml of ABC medium were added with constant rotating of the centrifuge tube as before, and the cells transferred again to the 37° C water bath for 1 minute.
- the centrifuge tube was removed from the water bath, and 4 ml of warm ABC medium were added, constantly rotating of the centrifuge tube as before.
- the cells were allowed to incubate for 1 minute at room temperature, after which 8 ml of warm ABC medium were added, constantly rotating of the centrifuge tube as before.
- the cells were allowed to incubate for 1 minute at room temperature, after which 12 ml of warm ABC medium were added with constant rotating of the centrifuge tube as before. Finally, the volume was brought to approximately 50 ml by addition of ABC medium.
- the cells were pelletted by centrifugation as described above. The medium was removed by aspiration and the cells resuspended in 60 ml of HM. These cells were then divided into two 30 ml aliquots, one receiving endothelial cell growth supplement (ECGS (available from Sigma, catalog # E2759), 5 ug/ml) and the other receiving no further supplements.
- ECGS endothelial cell growth supplement
- Cells were plated into 96 well dishes, 100 ⁇ l/well. Dishes labelled A,B,C received cells without ECGS; those with ECGS were in dishes labelled D,E,F. The cells were incubated in a humidified atmosphere of 5% CO2 in air.
- each well received 100 ⁇ l of 1X HAT medium, prepared in HM with or without ECGS as appropriate.
- HAT is a mixture of hypoxanthine, aminopterin and thymidine.
- the final concentrations used in the culture medium are 5x10 ⁇ 3 M hypoxanthine, 2x10 ⁇ 5 M aminopterin and 1x10 ⁇ 4 M thymidine.
- the cells were then allowed to incubate undisturbed for 144 hours, after which 50 ⁇ l of HM, without HAT, but with or without ECGS as appropriate, were added to each well.
- EIA enzyme-linked immunoassay
- the wells were then washed five times with PBS-T to remove unbound material and each well then received 100 ⁇ l of a 1 mg/ml solution of biotinylated anti-mouse IgG (Vector Laboratories, Burlingame, CA). The wells were again incubated at room temperature for 30-60 minutes and then washed five times with PBS-T to remove unbound material. Each well then received 100 ⁇ l of an avidin biotinylated horseradish peroxidase complex (AB complex; Vector Laboratories. The avidin portion of the AB complex binds with extraordinarily high affinity to the biotin portion of the biotinylated horse anti-mouse IgG, forming a stable, enzyme-containing complex).
- AB complex avidin biotinylated horseradish peroxidase complex
- the antibody molecules would bind to the inhibitors, and would therefore form an antibody-inhibitor complex which would stay in solution and be removed from the plate during the washing step.
- the binding of the antibody to the inhibitor would reduce the number of antibody molecules available to bind to the coating antigen, 651-BSA. Because fewer antibody molecules are attached to the 651-BSA, there is a reduction in the number of biotinylated horse anti-mouse IgG molecules bound, resulting in fewer molecules of avidin-peroxidase complex being bound, resulting in reduced hydrolysis of the substrate, leading ultimately to lower absorbances.
- CIEIA It is possible to manipulate the CIEIA to achieve greater inhibition by varying the concentrations of coating antigen, antibodies and detection molecules (such as the horse anti-mouse IgG and the avidin-peroxidase complex). Such "optimization" of the CIEIA is used to obtain higher levels of sensitivity and allow the use of lower concentrations (i.e. higher dilutions) of the monoclonal antibodies.
- Cloning was accomplished by first determining the total number of viable cells in a population of 89-147EH9 cells. The cell population was then diluted to a density of 4-5 cells per ml of cell culture medium. Two hundred ⁇ l of this cell suspension was then planted in each well of four 96 well cell culture dishes, designated I-IV. Fourteen days later, each well was checked by microscopic evaluation for growing colonies of cells. Those with only a single foci of cells were designated monoclonal. The results of the cloning procedure are shown in Table V below.
- clonal cell line 89-147EH9 IIIH6 was expanded, grown as ascites, purified and used in subsequent assays.
- a standard curve is generated by plotting the absorbance value vs. the log of the concentration of 651. The points are fitted using regression analysis, four parameter logistic curve fitting, or other statistical methods. The concentration of 651 in an unknown sample is then determined by comparing the absorbance values in wells in which the unknown samples were reacted with antibody, to the values obtained for the standard curve.
- a plastic strip is affixed to a vial cap so that it hangs down into a vial.
- On the surface of the dipstick is a two cm2 detection area to which is affixed 100 ng of anti-651 antibody.
- the sample is diluted into a vial containing a solution of 651-BSA conjugate (200 ng).
- the vial cap with the dipstick is screwed onto the vial and incubated for approximately 15-30 minutes.
- the dipstick is removed and rinsed with water or buffer and screwed onto a vial containing an avidin-HRP (horseradish peroxidase) complex, incubated for 15 min, and then rinsed.
- avidin-HRP horseradish peroxidase
- the dipstick is then placed in a vial containing HRP substrate such as azino-bis-ethylbenzthiazoline sulfonic acid ("ABTS").
- HRP substrate such as azino-bis-ethylbenzthiazoline sulfonic acid ("ABTS").
- Isothiazolone concentration is then estimated by determining the intensity of the blue colour in the vial after a specified incubation period.
- the anti-651 antibody is affixed to a membrane and the membrane (approximately two cm2 containing 100 ng antibody) is placed over a small cup.
- the sample is mixed with the 651-BSA-biotin conjugate (consisting of a 1:2 dilution of the sample, total amount of conjugate is 200 ng) and this solution poured over the membrane. Gravity pulls the solution through the membrane.
- a solution of avidin-HRP is poured over the membrane, rinsed, and then the detecting solution (HRP substrate) is poured over the membrane. Isothiazolone concentration is then estimated by determining the intensity of the blue colour on the membrane.
- Southern Yellow pine which had been pressure treated with a solution containing 4,5-dichloro-2-n-octyl-3-isothiazolone using commercial methods, was cut into wafers (0.5 x 2.5 cm). These wood wafers were soaked in a solution of 3% nonfat milk for 30 minutes. The wafers were then rinsed briefly with PBS-T, and then exposed to the anti-651 antibody, which is covalently linked to horseradish peroxidase at 500 ng/ml, for 15 minutes. The wafers were then washed twice for 30 minutes each in PBS-T buffer. The bound anti-651-HRP complex was visualized by placing the wafers in a vial containing HRP substrate (ABTS).
- ABTS horseradish peroxidase
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Organic Chemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Tropical Medicine & Parasitology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
- This invention relates to methods of detection of low concentrations of isothiazolone compounds using immunoassays.
- Isothiazolone compounds are widely used as biocides in many applications where water or moisture is present. In many of those applications, there is a need to determine the proper dosage and stability of the isothiazolone in the system. The present state of the art is to use HPLC analytical methods which are time consuming, inconvenient, and expensive.
- Westinghouse Electric Corporation EP 260829A discloses monoclonal antibodies which react with chlorinated phenols, particularly pentachlorophenol, and hybridomas which produce such antibodies; and an immunoassay for such chlorinated phenols. Although detection methods for many compounds would benefit greatly by development of an immunoassay, appropriate cell lines are very difficult to create.
- U.S. 4,865,972 (Hunter) discloses an antibody based assay for enzyme-inducing chemicals (such as dibenzodioxins). Isothiazolones are not enzyme-inducing compounds.
- Kohler and Milstein, Nature 265:495 (1975), first described how monoclonal antibodies directed to sheep red blood cells may be prepared by fusing a specific antibody-producing B-lymphocyte with a tumour cell, resulting in an "immortal" self-reproducing hybrid clone (or "hybridoma") that can synthesize, in a cell culture (in vitro) or an animal (in vivo), a single, monoclonal antibody.
- It is an object of the present invention to develop a further method of detecting isothiazolone compounds.
- We have discovered novel antibodies which satisfy a number of critical needs not fulfilled by existing analytical technology. Such antibodies allow the detection of isothiazolone by a variety of rapid, simple, and cost effective immunoassay techniques. The novel antibodies are particularly useful for analyzing the isothiazolone compound in water, since the isothiazolone does not have to be extracted first.
- Accordingly the present invention comprises in one aspect a method of preparing an immunogenic conjugate of an isothiazolone and a macromolecule carrier, comprising covalently attaching a macromolecule carrier to an isothiazolone containing a reactive group, preferably via a chemical linker; immunizing an animal with said immunogenic conjugate; obtaining antibody-producing cells from said animal; fusing said cells with tumour cells to produce hybridomas; selecting from among said hybridomas at least one hybridoma that produces antibodies able to bind specifically with said isothiazolones; and recovering said produced antibodies from said selected hybridoma.
- The invention is also directed to immunogenic conjugates of isothiazolones and a macromolecule carrier and to methods of making such conjugates.
- In a further aespect the invention comprises a method of producing polyclonal antibodies reactive with isothiazolones, comprising obtaining an immunogenic conjugate as described above; immunizing an animal with said conjugate; removing blood from said animal; separating the serum from said blood; and recovering polyclonal antibodies from said serum.
- The invention is directed to the antibodies, processes of preparing the antibodies, analytic, diagnostic, investigational, separatory, and the other methods of using the antibodies, and compositions containing the antibodies for such uses. In addition, the invention is directed to hybridomas that produce the monoclonal antibodies and to methods of making the hybridomas.
- FIG. 1 is a graph showing the percent inhibition of binding of four different species of isothiazolones of a immunoassay according to the invention.
- The isothiazolones as a class are very reactive electrophiles having a first order rate constant for reaction with thiols of 1.053 x 10³ mol/sec (P.J. Collier et al., J. Appl. Bacteriol., 69:578-584, 1991). Also, 5-chloro-2-methyl-3-isothiazolone has the capability of reacting further after the ring-opening reaction with thiols. It is well know that blood sera and red blood cells contain high levels of glutathione, a reduced thiol compound. Immediately after the introduction of isothiazolones into bovine serum, the isothiazolones are non-detectable by either bioassay, ultraviolet spectroscopy or high performance liquid chromatography (Proclin® 300 product bulletin, Rohm and Haas Company, Philadelphia, PA), implying the reaction of isothiazolone with a nucleophile and the destruction of the intact ring structure. This demonstrated rapid reaction of isothiazolones with nucleophiles known to be present in sera would lead one to predict that an intact isothiazolone introduced into an animal for the purpose of inducing antibody formation would not survive intact long enough to interact with the appropriate elements of the immune system. It is therefore quite unexpected that antibodies to isothiazolones can be induced.
- The use of polyclonal antibodies is possible, but the use of monoclonal antibodies is highly preferred. Monoclonal antibodies are derived from a single B-lymphocyte clone ("hybridoma") which makes them very specific and homogeneous. Such a hybridoma is, in fact, a self-reproducing cell "factory" which can produce a potentially limitless supply of an antibody with single, pre-defined specificity.
- While the monoclonal antibody of the present invention was developed against 5-chloro-2-methyl-3-isothiazolone ("651"), it has cross-reactivity with other isothiazolones, for example, 2-methyl-3-isothiazolone ("573"), 4,5-dichloro-2n-octyl-3-isothiazolone ("287"), and 2n-octyl-3-isothiazolone ("893") as shown in Figure 1.
- The preferred isothiazolones useful with this invention are of the formula
wherein R¹ and R² are each independently hydrogen, halogen or a (C₁-C₄) alkyl group or alternatively may be joined to form a saturated, unsaturated or aromatic 5- or 6-membered fused carbocyclic ring; Y is hydrogen, an unsubstituted or halo-substituted (C₁-C₁₈) alkyl group, an unsubstituted or halo-substituted alkenyl or alkynyl group of 2 to 8 carbons, an unsubstituted or halo-substituted (C₃-C₈) cycloalkyl, an (C₇-C₁₀)aralkyl or halo-, (C₁-C₄) alkyl-, or (C₁-C₄) alkoxy-substituted (C₇-C₁₀)aralkyl, or an aryl or halo-, (C₁-C₄) alkyl-, or (C₁-C₄) alkoxy-substituted aryl group of up to 10 carbon atoms. - Representative Y substituents include methyl, ethyl, propyl, isopropyl, butyl, hexyl, octyl, cyclohexyl, 4-methoxyphenyl, 4-chlorophenyl, 3,4-dichlorophenyl, benzyl, 4-methoxybenzyl, 4-chlorobenzyl, phenethyl, 4-phenylbutyl, chloromethyl, chloropropyl, hydrogen and the like.
- The most preferred isothiazolone is 5-chloro-2-methyl-3-isothiazolone.
- The monoclonal antibodies are made by producing an immunogenic conjugate of the isothiazolones and a macromolecule carrier, immunizing an animal with the conjugate, obtaining antibody-producing cells from the animal, fusing the cells with tumour cells to produce hybridomas, selecting from among the hybridomas at least one that produces antibodies reactive with isothiazolones, and recovering the produced antibodies from the selected hybridoma.
- An in vivo method of producing monoclonal antibodies reactive with isothiazolones involves intraperitoneally placing in a histocompatible or immunosuppressed host a hybridoma that produces such antibodies and recovering the produced antibodies from the ascites fluid of the host. A continuous cell line that produces monoclonal antibodies to isothiazolones is prepared by producing an immunogenic conjugate of the isothiazolones and a macromolecule carrier, immunizing an animal with the conjugate, obtaining antibody producing cells from the animal, fusing the antibody-producing cells with tumor cells to produce hybridomas, selecting from among the hybridomas a hybridoma that produces antibodies reactive with the isothiazolones, and clonally expanding the selected hybridoma into a cell line. The antibodies produced by the continuous cell line selected are referred to as "anti-651" antibodies.
- To detect the presence or concentrations of isothiazolones in a sample, monoclonal antibodies reactive with the isothiazolones are added to the sample and the presence or concentrations of the isothiazolones is determined by an immunoassay wherein the monoclonal antibodies are used as a reagent.
- The monoclonal antibodies are preferably provided in an acceptable carrier.
- The anti-651 antibody can be coupled to the enzyme horseradish peroxidase ("HRP") using standard procedures. This coupled enzyme-antibody can be used as an immunological stain to determine the location of isothiazolones in solid matrices such as wood, leather and plastics. The matrix to be examined is sectioned into thin slices by an appropriate method, and then incubated with the coupled enzyme-antibody for a period of time, during which it reacts with the isothiazolone or isothiazolones. After incubation, the unbound enzyme-antibody is removed by washing with buffer, such as PBS-Tween. Next, the treated matrix material is incubated with enzyme substrate, of which a number of commercially available chromogenic compounds are available. The matrix is treated with the substrate in such a volume that the coloured product does not diffuse away from the site of reaction. Alternatively, the substrate may be incorporated into a membrane which is overlaid on the treated substrate. An example of such a product is the Enzygraphic Web from International Biotechnologies Inc. ("IBZ"). The isothiazolone is localized by visual or microscopic examination of the matrix, or of the substrate-impregnated membrane.
- An alternative to the use of enzyme coupled antibody is the use of ferritin or gold-labelled antibody, or the use of radio-labelled antibodies. Radio-labelled antibodies require the exposure of the treated matrix to photographic film.
- The antibody can also be used to determine the presence and concentration of isothiazolones in a solid matrix, such as wood, plastic or leather. The solid matrix can be tested for the presence of isothiazolone by soaking wafers of the matrix in a solution of a protein blocking agent, such as nonfat milk or Bovine Serum Albumin ("BSA"), for 30-60 minutes. The wafers are then rinsed briefly with PBS-Tween (PBS-T) buffer, and exposed to the anti-651 antibody, which is covalently linked to horseradish peroxidase, for 15 minutes. The wafers are then washed twice for a period of time each in PBS-T buffer. The bound anti-651-HRP complex can then be visualized by placing the wafers in a vial containing HRP substrate, such as ABTS (2,2'-azino-bis-3- ethylbenzthiazolin-6-sulfonic acid). Alternatively, the enzyme substrate can be placed on the surface of the wood either as a solution or as a substrate affixed to a solid support, such as the commercially available Enzygraphic Web (IBI). The appearance of a colour indicates the presence of isothiazolone and the intensity of the colour relates to the concentration of the isothiazolone.
- An immunological procedure can be employed for the isolation or removal of isothiazolones from a mixture on the basis of a selective immunological reaction in which a monoclonal antibody reactive with the isothiazolones is used as the antibody.
- A composition for isolating or removing an isothiazolone compound from a mixture containing said compound comprises an effective amount of monoclonal antibody reactive with the isothiazolone compound, immobilized on a matrix or in admixture with a carrier.
- Polyclonal antibodies reactive with isothiazolone compound are produced by producing an immunogenic conjugate of the isothiazolone and a macromolecule carrier, immunizing an animal with the conjugate, removing blood from the animal, separating the serum from the blood, and recovering the antibodies from the serum.
- An immunogenic conjugate comprising isothiazolone compound covalently bonded to a macromolecule carrier is produced by covalently attaching a chemical linker to the macromolecule carrier and covalently attaching a derivative of the isothiazolone, such derivative containing a reactive group, to the chemical linker, thereby forming the immunogenic conjugate.
- In a particularly preferred embodiment, the monoclonal antibodies of the present invention have the characteristics of the monoclonal antibodies produced by the hybridoma cell line ATCC HB 11435 or mutants or variants thereof. ATCC HB 11435 is a biologically pure culture available from the permanent collection of the American Type Culture Collection (ATCC), 12301 Parklawn Drive, Rockville, Maryland USA 20852 and was deposited on May 14, 1991. ATCC HB 11435 was produced by fusion of a mouse B-lymphocyte and a mouse plasmacytoma cell. The immunoglobulins (antibodies) produced by these hybridomas are of the IgG class. The monoclonality of ATCC HB 11435 antibodies was ensured by re-cloning the hybridomas which produced them.
- The monoclonal antibodies produced by ATCC HB 11435 will prevent other monoclonal antibodies that would otherwise react with 5-chloro-2-methyl- 3-isothiazolone, which have been produced by other hybridomas, from so reacting.
- The hybridomas and continuous cell lines can be prepared by:
- (a) producing an immunogenic conjugate of a macromolecule carrier and the particular isothiazolones to which a monoclonal antibody is sought;
- (b) immunizing an animal with the conjugate;
- (c) obtaining antibody-producing cells from the animal;
- (d) fusing the antibody-producing cells with tumour cells to produce hybridomas;
- (e) screening from among the hybridomas a hybridoma that produces antibodies reactive with the immunogenic conjugates produced in step (a) supra;
to produce a cell line - (f) screening from among the hybridomas a hybridoma which produces antibodies reactive with free isothiazolones; and
- (g) cloning.
- The monoclonal antibodies can be recovered from the selected hybridoma or hybridomas before or after they are expanded by cloning into a continuous cell line.
- Alternatively, cells other than spleen cells can be used to produce antibodies to isothiazolones. The hybridomas produced by this embodiment can be used to produce the monoclonal antibodies of the invention by culturing them in a suitable medium and recovering the antibodies from the medium.
- Substances with molecular weights of approximately 1,000 or less, such as 5-chloro-2-methyl-3-isothiazolone (molecular weight 152), do not ordinarily induce the production of antibodies, i.e. they are non-immunogenic. However, such substances often can be chemically attached to larger, immunogenic carrier molecules, such as a carbohydrate or a protein, in order to induce the production of antibodies against the smaller substance, which is known as a hapten. The general techniques for producing an immunogenic conjugate of a hapten and a macromolecule carrier are known in the art. For example, see U.S. 4,456,691 to Stark, issued June 26, 1984 and Albro et al., Toxicol Appl. Pharmacol, 50. 137-146 (1979).
- The methods of Albro et al. and Stark involve covalently bonding the hapten to the macromolecule carrier through a chemical bridge or linker. The chemical linker is a bifunctional molecule that contains reactive groups on opposite ends. The reactive groups allow the chemical linker to react with reactive groups on the macromolecule and on the hapten so that one end of the chemical linker is covalently bonded to the hapten. The chemical linker is added first to the hapten and the resulting compound is then added to the macromolecule carrier through the reactive group at the other end of the chemical linker.
- It is known that antibodies raised against small chemical compounds conjugated to carrier proteins tend to recognize not only the structure of the chemical, but also the structures of the linker between chemical and protein, and even structures on the protein adjacent to the site of attachment of the linker. The results of such recognition of ancillary structures is the inability, or markedly reduced ability, of the antibody to bind to the free chemical. This is particularly a problem for monoclonal antibodies. This problem must be overcome if monoclonal antibodies to chemicals are to be useful for quantitative analysis. Surprisingly, we have discovered antibodies which perform this function with isothiazolone compounds, solving a long-felt need in the art.
- Once the immunogenic conjugate has been produced, it is used to immunize an animal host known by techniques. Such techniques usually involve inoculation, but they may involve other modes of administration. A sufficient amount of the conjugate is administered to create an immunogenic response in the animal host.
- Any host that produces antibodies to the conjugate may be used. Conventionally used animals include rabbits and rodents, such as rats or mice. Mice and rats are preferred for the present invention.
- Once the animal has been immunized and sufficient time has passed for it to begin producing antibodies to the conjugate, polyclonal antibodies may be recovered by techniques known in the art. The general method comprises removing blood from the animal and separating the serum from the blood. The serum, which contains antibodies to the isothiazolones used as the hapten in the preparation of the conjugate, may be used as an antiserum to the isothiazolones. Alternatively, the antibodies can be recovered from the serum. Affinity purification is a preferred technique for recovering purified polyclonal antibodies to isothiazolones from the serum.
- Monoclonal antibody-producing cells are recovered from the immunized animal. Although any antibody-producing cells may be used, B-lymphocytes obtained from the animal's spleen are preferred.
- The antibody-producing cells are fused with tumour cells to produce hybridomas. As used herein, the term "tumour cell" includes any cell that is capable of fusing with an antibody-producing cell to create a hybrid "immortal" cell, i.e., one which is capable of continuous growth in vitro. Preferred tumour cells are antibody-producing cells which have been transformed and which have lost their ability to produce immunoglobulin. Such cells include rat myeloma cells and mouse plasmacytoma cells. Particularly preferred are mouse plasmacytoma cells or rat myeloma cells that are deficient in the enzyme hypoxanthinequanine phosphoribosyl transferase (HGPRT), which allows the selection of hybridomas from unfused antibodying-producing cells or plasmacytoma or myeloma cells when grown on a medium containing hypoxanthine, aminopterin and thymidine.
- Various tumour cells useful for fusing with antibody-producing cells are known and readily available. One such type of cell is the mouse plasmacytoma cell line P3-X63-Ag8.653., described in Kearney, J. Immunology, 123. 1548 (1979). Another cell line is the rat myeloma cell line YB2.0, described in Milstein, J. Cell Biology, 93:576-582 (1982). These cell lines are available from American Type Culture Collection, Rockville, Maryland, where they are designated ATCC CRL 1580 and ATCC CRL 1662 respectively.
- It should be noted that the antibody-producing cell and the tumour cell can be from different animal species. For example, see Nowinski, et al. Science, 210:537 (1980).
- As mentioned previously, once the cells have been fused, it is necessary to separate the hybridomas from the unfused cells. The antibody-producing cells will normally die after a few days in culture, but the tumour cells are "immortal." However, by using tumour cells that are deficient in HGPRT and growing the fused cells on a medium containing hypoxanthine, aminopterin, and thymidine, the hybridomas will be naturally selected since the tumour cells are unable to survive on such a medium. However, other known selection techniques may also be used.
- After the hybridomas are selected, they are evaluated to determine which are producing antibodies to the isothiazolones. Various immunoassays known to those skilled in the art may be used to evaluate the culture supernatants of the hybridomas. Care must be taken to identify hybridomas that are producing monoclonal antibodies only to the isothiazolones rather than to the isothiazolone-macromolecule carrier. That is, the monoclonal antibodies which are desired, useful, and provided by this invention are those that react with free, i.e., unconjugated or unbound isothiazolones.
- The preferred selection technique is an initial screen by an enzyme immunoassay (EIA) to identify hybridomas producing antibodies to the conjugate or to the isothiazolones. These hybridomas are then screened by a competitive inhibition enzyme immunoassay (CIEIA) that evaluates the ability of a free isothiazolone, such as 5-chloro-2-methyl-3-isothiazolone, to inhibit the binding of monoclonal antibodies to the isothiazolone/protein carrier. The CIEIA is conducted according to the method disclosed in Hunter, et al., FEBS Lett. 149:147-151 (1982).
- Once the monoclonal antibody-producing hybridomas have been selected, the antibodies can be recovered from such hybridomas by known techniques. Generally, it is useful to clone one or more of the monoclonal antibody-producing hybridomas to expand it into a continuous cell line that can be used to produce the monoclonal antibodies in quantity.
- The previously mentioned methods of producing the monoclonal antibodies are in vitro methods. An in vivo process for producing monoclonal antibodies to isothiazolones includes placing a hybridoma that produces the antibodies intraperitoneally in a histocompatible or immunosuppressed host. This causes the host to produce ascites tumors which, in turn, produce a fluid that contains the monoclonal antibodies produced by the hybridoma. After a sufficient time has passed for the antibodies to have been produced in sufficient quantities, they may be recovered by known techniques. For example, the ascites fluid may be removed and the monoclonal antibodies recovered in pure form by affinity purification. This method is particularly suitable for producing the monoclonal antibodies in commercially useful quantities.
- Just as a variety of different systems and methods might be employed to produce monoclonal antibodies reactive with isothiazolones, so do a variety of monoclonal antibodies result from these measures that are distinct from the antibody illustrated in the Examples below. However, such monoclonal antibodies, whose production is enabled by the teachings therein, are still clearly within the scope of this invention. The salient feature of such antibodies, for the purposes of this invention, besides their monoclonality, is their reactivity in any way with isothiazolones, regardless of the species of origin, isotype, molecular specificity, affinity, method of production, or particular type of hybridoma employed in their production.
- The monoclonal and polyclonal antibodies can be used to identify isothiazolones, particularly 5-chloro-2-methyl-3-isothiazolone, in materials and to determine the concentration of the chemical in those materials. Such materials include, for example, soil, water, food, and body fluids. When used as a reagent in various immunoassays for determining the presence of concentration of isothiazolones, the antibodies of the present invention provide an improved assay. Detection is convenient, rapid, sensitive, and specific. The immunoassays in which the antibodies of the present invention may be used include, but are not limited to, radioimmunoassay, competition immunoprecipitation assay, enzyme-linked immunoabsorbent assay, and immunofluorescence assay. The monoclonal antibodies of the present invention are generally the preferred antibodies, although the polyclonal antibodies are preferred in certain applications.
- A composition for determining the presence or concentration of isothiazolones in material contains a concentration of antibodies to the chemical effective to detect the presence of the chemical or to quantify its amount. The antibodies can be mixed with or attached to any suitable carrier, such as a latex particle or plastic microtiter plate. They may also be conjugated with an enzyme or dye or radio-labelled, depending upon what immunological method is employed. Consequently, any assay system which employs monoclonal or polyclonal antibodies with isothiazolones, including 5-chloro-2-methyl-3-isothiazolone, is embraced by this invention.
- The monoclonal and polyclonal antibodies are also useful for the isolation, purification, neutralization, and/or removal of isothiazolones from complex mixtures of solutions on the basis of a selective immunological reaction. The use of antibodies reactive with isothiazolones represents an improvement over the known methods.
- Monoclonal antibodies are preferred over polyclonal antibodies. Because of their great specificity and their availability in virtually limitless quantities, monoclonal antibodies can be used on a large industrial or commercial scale. For example, anti-651 antibodies are useful to separate and purify 5-chloro-2-methyl-3-isothiazolone from a mixture of other isothiazolones or similar organic compounds. The mixture is brought into contact with immobilized monoclonal antibodies to 5-chloro-2-methyl-3-isothiazolone, which separates the 5-chloro-2-methyl-3-isothiazolone from the mixture by forming immobilized complexes of the 5-chloro-2-methyl-3-isothiazolone bound to the antibody. After the mixture is removed, the 5-chloro-2-methyl-3-isothiazolone is separated from the antibodies and recovered in purified form by known techniques.
- A composition useful for purifying or removing isothiazolones from complex mixtures contains an effective amount of the monoclonal antibody immobilized on an acceptable matrix or in admixture with an acceptable carrier, to permit reaction and binding with isothiazolones. However, for certain mixtures, polyclonal antibodies may be preferred.
- The monoclonal antibodies of this invention are also useful reagents for research related to the structure and function of isothiazolones, particularly 5-chloro-2-methyl-3-isothiazolone. Their specificity allows them to be used for immunochemical and structure-activity analyses of these chemicals, and makes them more useful in these applications than less specific polyclonal antibodies.
- The compositions are also useful as investigational reagents.
- The following non-limiting examples illustrate a few embodiments of the invention.
- Thionyl chloride (71.38 g, 0.6 mol) and pyridine (0.5 ml) were added to 3,3'-dithiodipropionic acid (21.03 g, 0.1 mol) with external cooling. This mixture was stirred at room temperature overnight. The excess thionyl chloride was removed in vacuo to yield 3,3'-dithiodipropionyl chloride as a light amber oil (23.7 g, 100 % yield) which was used in the next step without purification.
- A mixture of methyl 4-aminobutyrate·HCl (37.2 g, 0.242 mol) and triethylamine (67.8 ml, 0.486 mol) in ethylene dichloride (EDC, 300 ml) was stirred for 30 minutes at room temperature. The 3,3'-dithiodipropionyl chloride was dissolved in 50 ml EDC and added dropwise with cooling to the stirred solution, maintaining the temperature at approximately 25°C. The mixture was allowed to stir at room temperature overnight. The mixture was then poured into water and the organic layer separated. The organic layer was then washed with saturated NaHCO₃ solution, water, and then brine. The solution was then dried and concentrated to give a semi-solid brown residue. This residue was triturated in ethyl acetate with cooling to give 3,3'-dithio-di-N-(3-methoxycarbonylpropyl)propionamide (compound I) as an off-white solid which was filtered and dried (20.4 g).
- Compound I was cyclized to the isothiazolone. 3,3'-dithio-di-N-(3-methoxycarbonylpropyl)propionamide (12.0 g, 0.029 mol) and sulfuryl chloride (19.8 g, 0.147 mol) were charged concurrently over a one hour period to a flask containing cooled (0° C) and stirred ethyl acetate (120 ml). The amide and sulfuryl chloride were charged in 24 equal portions of 0.5 g and 0.5 ml respectively every 2.5 minutes. During the course of the addition, a precipitate formed. After addition was complete, the mixture was stirred at 0°C for 30 minutes and then allowed to warm to room temperature. The mixture was stirred for one hour at room temperature, cooled to 0°C and filtered. The solid was dissolved in water and extracted with CHCl₃. The CHCl₃ layer was washed with water and then brine. Once the CHCl₃ was dried, the solvent was removed to yield 5-chloro-2-(3-methoxycarbonylpropyl)-3-isothiazolone as a white solid (yield 8.9 g, m.p. 54-6°C).
- To prepare 2-(3-methoxycarbonylpropyl)-3-isothiazolone, Compound I (1.02 g, 2.5 mmol) was dissolved in 25 ml distilled ethyl acetate and cooled to 0° C. Sulfuryl chloride (1.04 g, 7.75 mmol) was added slowly dropwise and the yellow solution stirred at 0° C for 1 hr. During this time a white precipitate formed (5-chloro-2-(3-methoxycarbonylpropyl)-3-isothiazolone (200 mg)) which was removed by filtration. The resulting filtrate was concentrated and the residue flash-chromatographed (10% acetone-chloroform) to yield 2-(3-methoxycarbonylpropyl)-3-isothiazolone (120 mg) as a clear oil.
- The methyl ester of the isothiazolones were hydrolyzed to the free acids. 5-Chloro-2-(3-methoxycarbonylpropyl)-3-isothiazolone (4.0 g) was taken up in 6 ml of acetic acid. To this stirred solution at room temperature was added 6 M aqueous HCl (7 ml). This solution was then stirred at room temperature for 24 hours, during which time a white precipitate formed. The soultion was filtered and the filtrate further concentrated to yield more of the same precipitate (5-chloro-2-(3-hydroxy- carbonylpropyl)-3-isothiazolone). The combined yield was 2.95 g (m.p. 158-161° C).
- 2-(3-Methoxycarbonylpropyl)-3-isothiazolone was dissolved in a solution of 4 ml glacial acetic acid and 2 ml 6N hydrochloric acid. This was stirred at 85° C for 1 hr. The solution was concentrated in vacuuo and the residue partitioned between water and ethylacetate twice. The ethyl acetate layers were combined, dried and concentrated. The resulting solid was recrystallized from ethyl acetate to give a light yellow powder.
- The free acid isothiazolones were then coupled to bovine serum albumin ("BSA") and thyroglobulin ("THY"). 5-Chloro-2-(3-hydroxycarbonylpropyl)-3- isothiazolone (0.45 g, 0.002 mol) and n-Bu₃N (0.95 g, 0.0051 mol) were added to dioxane (5 ml). To this stirred suspension was added isobutylchloroformate (0.77g, 0.0056 mol) dropwise at 0°C. Upon addition of the isobutylchloroformate, the suspended material dissolved. This soluton was stirred at room temperature for 1 hour. This yielded the isothiazolone-isobutylformate mixed anhydride which was used without isolation. BSA was dissolved in deionized water (20 ml), followed by addition of a small amount of dioxane (1 ml). To this stirred BSA solution at 0°C was added dropwise the isothiazolone-isobutylformate mixed anhydride solution. The rate of addition was such that the reaction temperature was maintained at 0°C. After the addition was complete, the mixture was stirred at 0°C for one hour and then allowed to warm to room temperature, followed by stirring at room temperature for one hour. The mixture was then transferred to a dialysis bag and dialyzed for 24 hours and then lyophilized to remove water. A light, white powder (651-BSA conjugate) was obtained (2.9 g). The conjugates of 651 to THY (651-THY), 573 to BSA (573-BSA), and 573 to THY (573-THY) were prepared in a similar manner.
- BALB/c mice were obtained from Taconic Farms, New York, USA, and immunized with 651-BSA, 651-THY, 573-BSA or 573-THY conjugates produced in the previous Example according to the schedule set forth in Table I in which CFA is "Complete Freund's Adjuvant," IFAM "Incomplete Freund's Adjuvant," PBS is "Physiologically Buffered Saline," "sc" is subcutaneous, and "ip" is intraperitoneal.
TABLE I Day Date Amount Adjuvant Route 1 12/7/88 300 ug CFA sc 63 2/8/89 150 ug IFA sc 119 4/5/89 100 ug IFA sc 314 10/17/89 100 ug IFA sc 403 1/14/90 50 ug IFA sc 499 4/20/90 30 ug PBS ip 499 4/20/90 20 ug PBS sc 573 7/3/90 100 ug PBS ip - Blood samples were taken from the mice immunized in the above example. The sera were separated from the red blood cells by centrifugation. The sera were then screened for activity using competitive inhibition ELISA (CIEIA). Ninety-six well polystyrene EIA (enzyme inhibition assay) plates were coated with 100 µl of 651 conjugated to BSA (651-BSA), 651 conjugated to THY (651-THY), 573 conjugated to BSA (573-BSA), or 573 conjugated to THY (573-THY) for at least two hours at room temperature or 16 hours at 4° C. Unbound material was washed from the wells with five washes of PBS-T. The wells then received 50 µl of buffer alone (PBS-T) or inhibitors, either 651 or 573, each diluted to 2 ppm in buffer. The wells then received 50 µl of mouse serum, so that each serum was reacted with either buffer, 651 or 573 (inhibitors). The combination of equal volumes of sera and inhibitors or buffer resulted in a final concentration of inhibitors of 1 ppm. The wells were incubated for 30-60 minutes at room temperature. They were then washed five times with PBS-T to remove unbound material and each well then received 100 µl of a 1 µg/ml solution of biotinylated horse anti-mouse IgG (Vector Laboratories, Burlingame, CA), and the assay continued as described for the ELISA, supra.
- If the antibodies in a serum were reactive with one or both of the inhibitors in solution in the wells, the antibody molecules, or a percentage of the antibody molecules, would bind to the inhibitors, and would therefore form an antibody-inhibitor complex which would stay in solution and be removed from the plate during the washing step. In such a case, the binding of the antibody to the inhibitor would reduce the number of antibody molecules available to bind to the coating antigen, 651-BSA. Because fewer antibody molecules are attached to the 651-BSA, there is a reduction in the number of biotinylated horse anti-mouse IgG molecules bound, resulting in fewer molecules of avidin-peroxidase complex being bound, resulting in reduced hydrolysis of the substrate, leading ultimately to lower absorbances. The data are shown in Table 1A. In all cases, the inhibitor concentration was 10⁻⁴ M.
- These results indicate that mouse 1E, immunized with 573-THY, produced serum with antibodies reactive toward both 651 and 573.
- All techniques were performed aseptically and with sterile reagents. Mouse, 1E, producing polyclonal antibodies was killed by excess anesthesia (Rompum®/Ketamine®). The spleen was removed and placed in a 100 mm Petri dish containing approximately 20 ml of ABC medium (Cell Enterprises, Harrisonburg, VA). The spleen was then perfused with 10 ml of ABC medium to remove most of the splenocytes. The remaining cells were obtained by teasing apart the spleen capsule with 21 gauge needles. The volume was brought to approximately 50 ml with ABC medium and a 0.1 ml sample was removed and diluted 1:50 in ABC medium. The diluted cells were counted on a hemocytometer to obtain an approximation of the number of lymphocytes obtained from the spleen. During this time, the cells were pelletted by centrifugation at approximately 200 x g for 5 minutes at room temperature.
- Approximately, 1.2 x 10⁸ lymphocytes were obtained from the spleen. These were mixed with 1.2 x 10⁷ myeloma cells (SP2/0-Ag14, ATCC Cat CRL1581). The cells were again pelletted by centrifugation (approximately 250 x g for 10 minutes at room temperature). The supernatant was removed to near dryness and the cells resuspended by gently tapping the centrifuge tube to loosen the cell pellet.
- The cells were then treated with 1 ml of 50% polyethylene glycol, mw 1500 (PEG), which had been prewarmed to 36° C. The PEG was added slowly (dropwise) over a period of approximately 75 seconds, with constant rotating of the centrifuge tube to insure that the cells remained well mixed while in contact with PEG.
- The centrifuge tube containing the cells was then placed in a 37°C water bath for 1 minute. The tube was then removed from the water bath and 1 ml of warm ABC medium was added dropwise during the next 60-75 seconds with constant rotating of the centrifuge tube to insure that the cells and PEG were well mixed with the medium. The cells were again transferred to the 37° C water bath for 1 minute and then removed from the water bath. Over the next 60-75 seconds, 2 ml of ABC medium were added with constant rotating of the centrifuge tube as before, and the cells transferred again to the 37° C water bath for 1 minute. The centrifuge tube was removed from the water bath, and 4 ml of warm ABC medium were added, constantly rotating of the centrifuge tube as before. The cells were allowed to incubate for 1 minute at room temperature, after which 8 ml of warm ABC medium were added, constantly rotating of the centrifuge tube as before. The cells were allowed to incubate for 1 minute at room temperature, after which 12 ml of warm ABC medium were added with constant rotating of the centrifuge tube as before. Finally, the volume was brought to approximately 50 ml by addition of ABC medium.
- The cells were pelletted by centrifugation as described above. The medium was removed by aspiration and the cells resuspended in 60 ml of HM. These cells were then divided into two 30 ml aliquots, one receiving endothelial cell growth supplement (ECGS (available from Sigma, catalog # E2759), 5 ug/ml) and the other receiving no further supplements.
- Cells were plated into 96 well dishes, 100 µl/well. Dishes labelled A,B,C received cells without ECGS; those with ECGS were in dishes labelled D,E,F. The cells were incubated in a humidified atmosphere of 5% CO₂ in air.
- On day one after fusion, each well received 100 µl of 1X HAT medium, prepared in HM with or without ECGS as appropriate. (HAT is a mixture of hypoxanthine, aminopterin and thymidine. The final concentrations used in the culture medium are 5x10⁻³ M hypoxanthine, 2x10⁻⁵ M aminopterin and 1x10⁻⁴ M thymidine.) The cells were then allowed to incubate undisturbed for 144 hours, after which 50 µl of HM, without HAT, but with or without ECGS as appropriate, were added to each well.
-
- The supernatants from wells with growing colonies of hybridomas were screened using an enzyme-linked immunoassay (EIA). Ninety-six well polystyrene EIA plates were coated with 100 µl/well of 651 conjugated to BSA (651-BSA) for at least two hours at room temperature or 16 hours at 4° C. Unbound material was washed from the wells with five washes of PBS-T and wells then received 50 µl of PBS-T. Fifty µl of supernatant or culture medium alone (negative control) were then added to the wells and allowed to incubate for 30-60 minutes at room temperature. The wells were then washed five times with PBS-T to remove unbound material and each well then received 100 µl of a 1 mg/ml solution of biotinylated anti-mouse IgG (Vector Laboratories, Burlingame, CA). The wells were again incubated at room temperature for 30-60 minutes and then washed five times with PBS-T to remove unbound material. Each well then received 100 µl of an avidin biotinylated horseradish peroxidase complex (AB complex; Vector Laboratories. The avidin portion of the AB complex binds with extraordinarily high affinity to the biotin portion of the biotinylated horse anti-mouse IgG, forming a stable, enzyme-containing complex). After an incubation period of 30-60 minutes at room temperature, the unbound reagents were again washed from the wells with PBS-T, and each well received 100 µlof ABTS substrates (K&P). Absorbances (414 nm) were determined 30-60 minutes later using a FLOW Titertek Multiscan 340 EIA Plate reader.
- Screening of the hybridoma supernatants revealed two colonies producing antibodies reactive with the coating antigen. These colonies were designated 89-147EH9 and 89-147EC2. These cultures were expanded and cryopreserved and further evaluations were done by competitive inhibition ELISA (enzyme linked immunosorbtive assay) as described below.
- The supernatants from wells with growing colonies of hybridomas were screened using CIEIA. Ninety-six well polystyrene EIA (enzyme inhibition assay) plates were coated with 100 µl of 651 conjugated to BSA (651-BSA) for at least two hours at room temperature or 16 hours at 4° C. Unbound material was washed from the wells with five washes of PBS-T. The wells then received 50 µl of buffer alone (PBS-T) or inhibitors, either 651 or 573, each diluted to 2 ppm in buffer. The wells then received 50µl of supernatant from each cell culture, so that each supernatant was reacted with either buffer, 651 or 573 (inhibitors). The combination of equal volumes of supernatants and inhibitors or buffer resulted in a final dilution of the supernatants of 1:2 and a final concentration of inhibitors of 1 ppm. The wells were incubated for 30-60 minutes at room temperature. They were then washed five times with PBS-T to remove unbound material and each well then received 100 µl of a 1 µg/ml solution of biotinylated horse anti-mouse IgG (Vector Laboratories, Burlingame, CA), and the assay continued as described for the ELISA, supra.
- If the antibodies in a supernatant were reactive with one or both of the inhibitors in solution in the wells, the antibody molecules, or a percentage of the antibody molecules, would bind to the inhibitors, and would therefore form an antibody-inhibitor complex which would stay in solution and be removed from the plate during the washing step. In such a case, the binding of the antibody to the inhibitor would reduce the number of antibody molecules available to bind to the coating antigen, 651-BSA. Because fewer antibody molecules are attached to the 651-BSA, there is a reduction in the number of biotinylated horse anti-mouse IgG molecules bound, resulting in fewer molecules of avidin-peroxidase complex being bound, resulting in reduced hydrolysis of the substrate, leading ultimately to lower absorbances.
- It is possible to manipulate the CIEIA to achieve greater inhibition by varying the concentrations of coating antigen, antibodies and detection molecules (such as the horse anti-mouse IgG and the avidin-peroxidase complex). Such "optimization" of the CIEIA is used to obtain higher levels of sensitivity and allow the use of lower concentrations (i.e. higher dilutions) of the monoclonal antibodies.
-
- To demonstrate that the antibodies produced by cell culture 89-147EH9 reacted preferentially with compound 651, a CIEIA was performed as described above, except that the antibody-containing supernatants were reacted with four different inhibitors, each at several different concentrations. The results of this procedure are presented in Table IV. The antibodies in this invention are more strongly reactive with 651 than with the other compounds tested, as evidenced by higher levels of inhibition with 651 than with similar amounts of other biocides.
- In order to assure that the antibodies reactive with compound 651 were produced by cells of the identical genetic makeup, it was necessary to derive clones of cell culture 89-147EH9. Cloning was accomplished by first determining the total number of viable cells in a population of 89-147EH9 cells. The cell population was then diluted to a density of 4-5 cells per ml of cell culture medium. Two hundred µl of this cell suspension was then planted in each well of four 96 well cell culture dishes, designated I-IV. Fourteen days later, each well was checked by microscopic evaluation for growing colonies of cells. Those with only a single foci of cells were designated monoclonal. The results of the cloning procedure are shown in Table V below.
TABLE V Cloning of Cell Culture 89-147EH9 Plate ID Wells with Colonies Wells with Single Foci % With Single Foci I 15 11 73.3 II 17 12 70.6 III 19 17 89.5 IV 18 13 72.2 TOTALS 17.25+/1.7 13.25+/-2.6 76.4+/-8.8 -
- Based on the results of these and subsequent assays, clonal cell line 89-147EH9 IIIH6 was expanded, grown as ascites, purified and used in subsequent assays.
- In order to demonstrate the utility of the CIEIA for determining 651 concentrations in unknown samples, a quantitative immunoassay was developed. This assay is performed as described in Example 4, except that replicate samples of antibody are reacted with a series of known concentrations of compound 651, as well as with several dilutions of samples containing unknown amounts of 651. As described in Example 4, at the highest concentrations of 651, maximal interaction of the antibody with 651 occurs, ultimately leading to reduced absorbance values. Intermediate levels of 651 cause moderate reduction in absorbance values, and low levels of 651 cause little or no reduction in absorbance values.
- In the quantitative CIEIA, a standard curve is generated by plotting the absorbance value vs. the log of the concentration of 651. The points are fitted using regression analysis, four parameter logistic curve fitting, or other statistical methods. The concentration of 651 in an unknown sample is then determined by comparing the absorbance values in wells in which the unknown samples were reacted with antibody, to the values obtained for the standard curve.
- These procedures were used to estimate the concentrations of 651 in laboratory prepared samples of papermill fluid, cooling tower water and metal working fluid (MWF), all at use dilutions. The results of these assays are presented in Table VII, along with the actual concentrations in the sample. These results indicate that this assay can be used to successfully estimate the level of 651 in a sample.
-
- In the dipstick kit format, a plastic strip is affixed to a vial cap so that it hangs down into a vial. On the surface of the dipstick is a two cm² detection area to which is affixed 100 ng of anti-651 antibody. The sample is diluted into a vial containing a solution of 651-BSA conjugate (200 ng). The vial cap with the dipstick is screwed onto the vial and incubated for approximately 15-30 minutes. The dipstick is removed and rinsed with water or buffer and screwed onto a vial containing an avidin-HRP (horseradish peroxidase) complex, incubated for 15 min, and then rinsed. The dipstick is then placed in a vial containing HRP substrate such as azino-bis-ethylbenzthiazoline sulfonic acid ("ABTS"). Isothiazolone concentration is then estimated by determining the intensity of the blue colour in the vial after a specified incubation period.
- The anti-651 antibody is affixed to a membrane and the membrane (approximately two cm² containing 100 ng antibody) is placed over a small cup. The sample is mixed with the 651-BSA-biotin conjugate (consisting of a 1:2 dilution of the sample, total amount of conjugate is 200 ng) and this solution poured over the membrane. Gravity pulls the solution through the membrane. Next, a solution of avidin-HRP is poured over the membrane, rinsed, and then the detecting solution (HRP substrate) is poured over the membrane. Isothiazolone concentration is then estimated by determining the intensity of the blue colour on the membrane.
- Southern Yellow pine, which had been pressure treated with a solution containing 4,5-dichloro-2-n-octyl-3-isothiazolone using commercial methods, was cut into wafers (0.5 x 2.5 cm). These wood wafers were soaked in a solution of 3% nonfat milk for 30 minutes. The wafers were then rinsed briefly with PBS-T, and then exposed to the anti-651 antibody, which is covalently linked to horseradish peroxidase at 500 ng/ml, for 15 minutes. The wafers were then washed twice for 30 minutes each in PBS-T buffer. The bound anti-651-HRP complex was visualized by placing the wafers in a vial containing HRP substrate (ABTS). The appearance of a blue color in the solution indicated the presence of 4,5-dichloro-2-n-octyl-3-isothiazolone. A 200 µl aliquot of the solution in the vial was taken and the absorbance determined at 405 nm. This was compared to a control wood wafer treated in an identical manner but containing no isothiazolone. The absorbance values were then corrected for background.
Sample A₄₀₅ Control 0.002 Treated 0.165
These data show that this method could be used for the determination of the isothiazolone concentration in wood or a solid matrix.
Claims (16)
- A method of preparing an immunogenic conjugate of an isothiazolone and a macromolecule carrier, comprising covalently attaching a macromolecule carrier to an isothiazolone containing a reactive group, preferably via a chemical linker.
- A method of producing monoclonal antibodies reactive with isothiazolones comprising immunizing an animal with an immunogenic conjugate produced in accordance with claim 1; obtaining antibody-producing cells from said animal; fusing said cells with tumour cells to produce hybridomas; selecting from among said hybridomas at least one hybridoma that produces antibodies able to specifically bind to said isothiazolones; and recovering said produced antibodies from said selected hybridoma.
- A method according to claim 2 wherein said animal is a rodent, and said tumour cells are preferably mouse plasmacytoma or rat myeloma cells.
- A method according to claim 2 or 3 characterized in that the hybridomas have all of the identifying characteristics of ATCC HB 11435 or mutants or variants thereof.
- A method according to claim 3 or 4 wherein said animal is a mouse, and said method comprises the steps of recovering antibody-producing cells from the spleen thereof, fusing them with mouse plasmacytoma or rat myeloma cells deficient in the enzyme hypoxanthineguanine phosphoribosyl transferase to form hybridomas, at least one of which is selected by growth in a medium comprising hypoxanthine, aminopterin, and thymidine; identifying at least one of said hybridomas that produces an antibody to isothiazolone in free or unconjugated form; culturing said identified hybridoma to produce said antibody in a recoverable quantity; and recovering the antibodies produced by said cultured hybridoma.
- A method according to claim 2, 3 or 4 wherein the antibodies reactive with isothiazolones are recovered from the hybridoma by intraperitoneally placing said hybridoma in a histocompatible or immunosuppressed host and recovering antibodies from the ascites fluid of said host.
- A method according to any one of claims 2 to 6 further comprising the step of clonally expanding said selected hybridoma into a continuous cell line.
- A method of producing polyclonal antibodies reactive with isothiazolones, comprising obtaining an immunogenic conjugate according to claim 1; immunizing an animal with said conjugate; removing blood from said animal; separating the serum from said blood; and recovering polyclonal antibodies from said serum.
- An immunogenic concentrate comprising an isothiazolone derivative covalently attached via a reactive group to a chemical linker, which is itself covalently attached to a macromolecule carrier.
- Hybridoma which produces a monoclonal antibody able to bind specifically to isothiazolones.
- Hybridoma according to claim 10 having all of the identifying characteristics of ATCC HB 11435 or mutants or variants thereof.
- Monoclonal or polyclonal antibody reactive with isothiazolones.
- Monoclonal antibody according to claim 12 which is recovered from a continuous cell line or a hybridoma, preferably a hybridoma as defined in claim 11.
- A method for determining the presence or concentration of isothiazolones in a composition comprising employing an immunoassay having as a reagent a monoclonal or polyclonal antibody produced according to any one of claims 2 to 8.
- A method for isolating or removing isothiazolones from a composition comprising bringing a specimen of said composition and a monoclonal antibody produced according to any one of claims 2 to 8 into contact for a period of time, and thereafter measuring the concentration of antigen in said specimen by determining the amount of antigen-antibody complex resulting from said contact.
- A method, antibody, hybridoma or immunogenic conjugate according to any preceding claim, wherein said isothiazolone is 2-methyl-3-isothiazolone or 5-chloro-2-methyl-3-isothiazolone.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US92776592A | 1992-09-28 | 1992-09-28 | |
US927765 | 1992-09-28 |
Publications (2)
Publication Number | Publication Date |
---|---|
EP0592127A1 true EP0592127A1 (en) | 1994-04-13 |
EP0592127B1 EP0592127B1 (en) | 1998-04-15 |
Family
ID=25455220
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP93307558A Expired - Lifetime EP0592127B1 (en) | 1992-09-28 | 1993-09-23 | Immunoassay for isothiazolones |
Country Status (19)
Country | Link |
---|---|
US (1) | US5554542A (en) |
EP (1) | EP0592127B1 (en) |
JP (1) | JPH07294522A (en) |
KR (1) | KR940006604A (en) |
CN (1) | CN1090929A (en) |
AT (1) | ATE165009T1 (en) |
AU (1) | AU675802B2 (en) |
BR (1) | BR9303898A (en) |
CA (1) | CA2106693A1 (en) |
CZ (1) | CZ202693A3 (en) |
DE (1) | DE69317976T2 (en) |
DK (1) | DK0592127T3 (en) |
ES (1) | ES2115022T3 (en) |
HU (1) | HU214700B (en) |
IL (1) | IL107055A0 (en) |
MY (1) | MY109450A (en) |
SG (1) | SG81877A1 (en) |
TW (1) | TW258789B (en) |
ZA (1) | ZA937028B (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2005201412B2 (en) * | 2004-04-06 | 2010-03-04 | Arxada Nz Limited | Method For Determining Biocides Within Wood |
US9822171B2 (en) | 2010-04-15 | 2017-11-21 | AbbVie Deutschland GmbH & Co. KG | Amyloid-beta binding proteins |
US10464976B2 (en) | 2003-01-31 | 2019-11-05 | AbbVie Deutschland GmbH & Co. KG | Amyloid β(1-42) oligomers, derivatives thereof and antibodies thereto, methods of preparation thereof and use thereof |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6218181B1 (en) | 1998-03-18 | 2001-04-17 | The Salk Institute For Biological Studies | Retroviral packaging cell line |
WO2007001192A1 (en) * | 2005-06-28 | 2007-01-04 | Matthews, John, Brodie | Method of determining biocides within wood |
SG2014013437A (en) | 2005-11-30 | 2014-07-30 | Abbott Lab | Monoclonal antibodies and uses thereof |
RU2442793C2 (en) | 2005-11-30 | 2012-02-20 | Эбботт Лэборетриз | ANTISUBSTANCES AGAINST GLOBULOMER Aβ, THEIR ANTIGEN-BINDING PARTS, CORRESPONDING HYBRIDOMAS, NUCLEIC ACIDS, VECTORS, HOST CELLS, WAYS OF PRODUCTION OF MENTIONED ANTISUBSTANCES, COMPOSITIONS CONTAINING MENTIONED ANTISUBSTANCES, APPLICATION OF MENTIONED ANTISUBSTANCES AND WAYS OF APPLICATION OF MENTIONED ANTISUBSTANCES |
US8455626B2 (en) | 2006-11-30 | 2013-06-04 | Abbott Laboratories | Aβ conformer selective anti-aβ globulomer monoclonal antibodies |
US20100311767A1 (en) | 2007-02-27 | 2010-12-09 | Abbott Gmbh & Co. Kg | Method for the treatment of amyloidoses |
JP6147665B2 (en) | 2010-08-14 | 2017-06-14 | アッヴィ・インコーポレイテッド | Amyloid beta-binding protein |
US8912003B2 (en) | 2011-08-26 | 2014-12-16 | General Electric Company | Methods and devices for detecting isothiazolones |
KR20210065991A (en) * | 2018-09-27 | 2021-06-04 | 피에르 파브르 메디카먼트 | Sulfomaleimide-based linkers and corresponding conjugates |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0260829A2 (en) * | 1986-09-15 | 1988-03-23 | Westinghouse Electric Corporation | Antibodies reactive with chlorinated phenols and methods of preparing and using same |
US4865972A (en) * | 1986-08-22 | 1989-09-12 | Westinghouse Electric Corp. | Antibody-based bioassay for enzyme-inducing chemicals |
WO1992003727A1 (en) * | 1990-08-15 | 1992-03-05 | Cts Biocides Ltd. | Assay for isothiazolones |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4456691A (en) * | 1983-02-28 | 1984-06-26 | Suad Stark | Antigen for PCB, antibody raised by same, and method of making same |
US4652530A (en) * | 1985-07-15 | 1987-03-24 | Rohm And Haas Company | Monitoring method for isothiazolones in aqueous systems |
US5094957A (en) * | 1990-12-10 | 1992-03-10 | Rohm And Haas Company | Quantitative method for determining concentration of 3-isothiazolone |
-
1993
- 1993-09-01 TW TW082107115A patent/TW258789B/zh active
- 1993-09-21 IL IL93107055A patent/IL107055A0/en unknown
- 1993-09-22 AU AU47524/93A patent/AU675802B2/en not_active Ceased
- 1993-09-22 CA CA002106693A patent/CA2106693A1/en not_active Abandoned
- 1993-09-23 DK DK93307558T patent/DK0592127T3/en active
- 1993-09-23 AT AT93307558T patent/ATE165009T1/en not_active IP Right Cessation
- 1993-09-23 EP EP93307558A patent/EP0592127B1/en not_active Expired - Lifetime
- 1993-09-23 ES ES93307558T patent/ES2115022T3/en not_active Expired - Lifetime
- 1993-09-23 DE DE69317976T patent/DE69317976T2/en not_active Expired - Fee Related
- 1993-09-23 ZA ZA937028A patent/ZA937028B/en unknown
- 1993-09-23 SG SG9604229A patent/SG81877A1/en unknown
- 1993-09-24 BR BR9303898A patent/BR9303898A/en not_active Application Discontinuation
- 1993-09-25 MY MYPI93001955A patent/MY109450A/en unknown
- 1993-09-27 HU HU9302736A patent/HU214700B/en not_active IP Right Cessation
- 1993-09-28 CN CN93119841A patent/CN1090929A/en active Pending
- 1993-09-28 US US08/128,451 patent/US5554542A/en not_active Expired - Fee Related
- 1993-09-28 CZ CZ932026A patent/CZ202693A3/en unknown
- 1993-09-28 JP JP5264302A patent/JPH07294522A/en active Pending
- 1993-09-28 KR KR1019930020143A patent/KR940006604A/en not_active Application Discontinuation
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4865972A (en) * | 1986-08-22 | 1989-09-12 | Westinghouse Electric Corp. | Antibody-based bioassay for enzyme-inducing chemicals |
EP0260829A2 (en) * | 1986-09-15 | 1988-03-23 | Westinghouse Electric Corporation | Antibodies reactive with chlorinated phenols and methods of preparing and using same |
WO1992003727A1 (en) * | 1990-08-15 | 1992-03-05 | Cts Biocides Ltd. | Assay for isothiazolones |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10464976B2 (en) | 2003-01-31 | 2019-11-05 | AbbVie Deutschland GmbH & Co. KG | Amyloid β(1-42) oligomers, derivatives thereof and antibodies thereto, methods of preparation thereof and use thereof |
AU2005201412B2 (en) * | 2004-04-06 | 2010-03-04 | Arxada Nz Limited | Method For Determining Biocides Within Wood |
US9822171B2 (en) | 2010-04-15 | 2017-11-21 | AbbVie Deutschland GmbH & Co. KG | Amyloid-beta binding proteins |
Also Published As
Publication number | Publication date |
---|---|
DK0592127T3 (en) | 1999-01-04 |
HUT67054A (en) | 1995-01-30 |
IL107055A0 (en) | 1993-12-28 |
AU675802B2 (en) | 1997-02-20 |
HU214700B (en) | 1998-08-28 |
AU4752493A (en) | 1994-04-14 |
CA2106693A1 (en) | 1994-03-29 |
BR9303898A (en) | 1994-06-14 |
KR940006604A (en) | 1994-04-25 |
HU9302736D0 (en) | 1994-01-28 |
EP0592127B1 (en) | 1998-04-15 |
SG81877A1 (en) | 2001-07-24 |
JPH07294522A (en) | 1995-11-10 |
CZ202693A3 (en) | 1994-04-13 |
ATE165009T1 (en) | 1998-05-15 |
DE69317976D1 (en) | 1998-05-20 |
MY109450A (en) | 1997-01-31 |
ZA937028B (en) | 1994-03-29 |
DE69317976T2 (en) | 1998-11-12 |
ES2115022T3 (en) | 1998-06-16 |
TW258789B (en) | 1995-10-01 |
CN1090929A (en) | 1994-08-17 |
US5554542A (en) | 1996-09-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0592127B1 (en) | Immunoassay for isothiazolones | |
EP0363041A1 (en) | Monoclonal antibody to morphine, preparation of monoclonal antibody, assaying kit and assaying method of morphine | |
EP0260829A2 (en) | Antibodies reactive with chlorinated phenols and methods of preparing and using same | |
EP0311383B1 (en) | Monoclonal antibody to methamphetamine, preparation of the same, assay method and assay kit of methamphetamine | |
CN111912986B (en) | Broad-spectrum type microcystin enzyme-linked immunoassay kit | |
JP3947283B2 (en) | Hapten compound, antibody and measuring method of iprodione and its metabolite | |
JP3188641B2 (en) | Hapten compound of microbutanil, antibody and method of measurement | |
EP0258006A2 (en) | Monoclonal antibodies reactive with chlorinated dibenzo-p-dioxins and method of preparing and using same | |
JP2000191699A (en) | Monoclonal antibody to be specifically reacted with coplanar pcb substantially not reducing antigen recognition characteristic even in 50 (v/v)% aqueous solution of organic solvent, and its measurement | |
JPH05317085A (en) | Immunologic detecting method | |
JP3188642B2 (en) | Hapten compound of imazalil, antibody and measuring method | |
JP2000095769A (en) | Hapten compound of probenazole, antibody and assay | |
JP3015306B2 (en) | Hapten compound of acid amide compound, antibody and measurement method | |
HU206772B (en) | Method and reagent set for immunological detecting atrazine and atrazine-derivatives and method for obtaining monoclonic antibiotics suitable to said detection | |
JP2993902B2 (en) | Hapten compound of triflumizole, antibody and measuring method | |
JP4221119B2 (en) | Specific antibody against domoic acid and immunological analysis of domoic acid | |
Dean | Preparation and characterization of monoclonal antibodies to proteins and other cellular components | |
US20010039332A1 (en) | Monoclonal antibodies to 4,4'-dinitrocarbanilide and a method for analyzing for the drug nicarbazin | |
AU588573B2 (en) | An antibody preparation and processes for its manufacture and use | |
JP4639348B2 (en) | Antibody specific to halogenated benzylate compound, method for producing the antibody, and immunological assay | |
JP3161513B2 (en) | Pyrazosulfuron derivative, anti-pyrazosulfuron-ethyl antibody, hybridoma secreting the same, and method for analyzing pyrazosulfuron-ethyl | |
JP2000239239A (en) | Hapten compound of chlormequat-related compound, antibody and its determination | |
JPH0549494A (en) | Immunologic detecting method | |
JPH11255786A (en) | Hapten of triclofos methyl, its antibody and determination | |
JP2001039953A (en) | Haptenic compound for pyriminobac-methyl, antibody and measurement |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 19931005 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU NL PT SE |
|
17Q | First examination report despatched |
Effective date: 19961212 |
|
GRAG | Despatch of communication of intention to grant |
Free format text: ORIGINAL CODE: EPIDOS AGRA |
|
GRAG | Despatch of communication of intention to grant |
Free format text: ORIGINAL CODE: EPIDOS AGRA |
|
GRAH | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOS IGRA |
|
GRAH | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOS IGRA |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU NL PT SE |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 19980415 |
|
REF | Corresponds to: |
Ref document number: 165009 Country of ref document: AT Date of ref document: 19980515 Kind code of ref document: T |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
ITF | It: translation for a ep patent filed |
Owner name: JACOBACCI & PERANI S.P.A. |
|
REF | Corresponds to: |
Ref document number: 69317976 Country of ref document: DE Date of ref document: 19980520 |
|
ET | Fr: translation filed | ||
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2115022 Country of ref document: ES Kind code of ref document: T3 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D Free format text: 79795 |
|
REG | Reference to a national code |
Ref country code: PT Ref legal event code: SC4A Free format text: AVAILABILITY OF NATIONAL TRANSLATION Effective date: 19980417 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 19980923 Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 19980923 Ref country code: DK Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 19980923 Ref country code: AT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 19980923 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 19980924 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 19980930 |
|
REG | Reference to a national code |
Ref country code: DK Ref legal event code: T3 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
BERE | Be: lapsed |
Owner name: ROHM AND HAAS CY Effective date: 19980930 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 19990401 |
|
26N | No opposition filed | ||
EUG | Se: european patent has lapsed |
Ref document number: 93307558.2 |
|
NLV4 | Nl: lapsed or anulled due to non-payment of the annual fee |
Effective date: 19990401 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20000331 |
|
REG | Reference to a national code |
Ref country code: PT Ref legal event code: MM4A Free format text: LAPSE DUE TO NON-PAYMENT OF FEES Effective date: 20000331 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20000807 Year of fee payment: 8 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20000811 Year of fee payment: 8 Ref country code: CH Payment date: 20000811 Year of fee payment: 8 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 20000823 Year of fee payment: 8 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: ES Payment date: 20000912 Year of fee payment: 8 |
|
REG | Reference to a national code |
Ref country code: DK Ref legal event code: EBP |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20010923 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: ES Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20010924 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20010930 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20010930 |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: IF02 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20020501 |
|
GBPC | Gb: european patent ceased through non-payment of renewal fee |
Effective date: 20010923 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20020531 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: ST |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FD2A Effective date: 20021011 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES;WARNING: LAPSES OF ITALIAN PATENTS WITH EFFECTIVE DATE BEFORE 2007 MAY HAVE OCCURRED AT ANY TIME BEFORE 2007. THE CORRECT EFFECTIVE DATE MAY BE DIFFERENT FROM THE ONE RECORDED. Effective date: 20050923 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 19980923 |